British research shows that the COVID-19 vaccine reduces the risk of cardiovascular complications

Almost as soon as the COVID-19 pandemic broke out, the ruling class campaigned vigorously against any measures that, while fighting the virus, could hinder their ability to accumulate profits.

The world’s governments quickly adopted a vaccine-only strategy, pushing aside other public health measures. This has now largely been replaced by a total ‘let it rip’ policy, as even vaccines become more difficult to access, for the populations that once had access to them in large numbers.

To justify this destructive course of action, information about the virus has been withheld or misrepresented, and various pseudoscientific claims have been made to downplay the severity of the disease. This has created a fertile environment for backward anti-vaccine views and conspiracy theories, which are openly supported by some of the most deranged sections of the ruling class.

One of the arguments most often cited by “anti-vaxers” is the existence of some cases in which people developed cardiovascular complications after vaccination – a small number of which resulted in the tragic deaths of the vaccinated individuals. They argue that the possibility of said complications justifies rejection of the vaccine, thereby minimizing or negating the vaccine’s benefits in preventing COVID-19, a serious disease with a significant mortality rate and very well-documented, life-altering long-term consequences term. .

A study published in the journal Nature communication refutes this claim by analyzing the incidence of cardiovascular complications in a very large population of vaccinated individuals.

Research led by the Universities of Cambridge, Bristol and Edinburgh – and powered by Health Data Research UK’s British Heart Foundation (BHF) Data Science Center – analyzed anonymised health records from 46 million adults in England between December 8, 2020 and January 23, 2022.

Data scientists compared the incidence of cardiovascular disease after vaccination with the incidence before or without vaccination, during the first two years of the vaccination program. They specifically evaluated the incidence of cardiovascular and thrombotic events after the first, second and booster doses of COVID-19 vaccines from December 2020 to January 2022. The vaccines studied included the mRNA vaccines (Pfizer’s BNT-162b2 and Moderna’s mRNA-1273) and the adenovirus-based ChAdOx1 vaccine (AstraZeneca).

The study used Cox regression models to calculate adjusted hazard ratios (aHRs), which compare the risk of cardiovascular events after vaccination with the risk before or without vaccination. Across all doses and vaccine types, the incidence of thrombotic events (e.g. blood clots) was lower after vaccination, for both arterial and venous events. The reduction was already visible after the first dose, with a 10 percent lower risk of arterial thrombotic events after receiving the first dose of the Pfizer vaccine.